Faisal Ghiath Sukhtian, Director at Outlook Therapeutics, Inc. (OTLK), bought 10,000 shares at $0.67 ($7K) on 2020-09-17, disclosed to the SEC on 2020-09-17.
Open-market purchase of $7k OTLK by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history).
Something here stands out, but not much.
| Filing → |
| OTLK | BUY | 2022-10-11 | $39K | — | Filing → |
| OTLK | BUY | 2021-12-02 | $25K | — | Filing → |
| OTLK | BUY | 2021-04-20 | $18K | — | Filing → |